<DOC>
	<DOCNO>NCT00702754</DOCNO>
	<brief_summary>Five hundred patient confirm clinical diagnosis Cervical Dystonia ( CD ) plan enrollment open label study . These patient Type B toxin naive patient CD . During study patient receive repeat injection MYOBLOC deem appropriate Investigator . However , recommend injection occur frequently every 12 week . Total duration exposure MYOBLOC target least two year , potential exposure 7 year patient earliest enrollment</brief_summary>
	<brief_title>An Open Label Safety Immunogenicity Study MYOBLOC ( Neurobloc ; Botulinum Toxin Type B ) Injectable Solution Patients With Cervical Dystonia</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>rimabotulinumtoxinB</mesh_term>
	<criteria>18 year age old body weight least 46 kilogram History Cervical Dystonia least one year 's duration opinion Investigator require treatment Inability give inform consent Patient previously treat botulinum Toxin Type B Patient receive Botulinum toxin Type A injection last 12 week . History phenol injection involve neck shoulder region last 12 month . Patients neck contracture cervical spine disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>